Ara-290

Ara-290 (cibinetide) is described as a non-erythropoietic peptide that targets tissue repair and inflammation control without stimulating red blood cell production. Mechanistically, the protocol explains that Ara-290 binds the ‘innate repair receptor’—a heterodimer of EPOR and CD131 (βc subunit)—which is distinct from the classic erythropoietin receptor responsible for erythropoiesis. By selectively activating the repair receptor, Ara-290 is described as triggering anti-apoptotic and anti-inflammatory signaling cascades that shift an injury environment from tissue-damaging inflammation toward healing and regeneration. The page also highlights analgesic mechanisms, including immunomodulation and reported direct inhibition of TRPV1 ion channels (capsaicin-activated), which can contribute to pain reduction. Clinical trial contexts summarized include diabetic neuropathy and sarcoidosis-associated small-fiber neuropathy, where improvements in pain and objective nerve-regrowth markers are described. Overall, Ara-290 is framed as a repair-signaling peptide with a favorable tolerability profile in reported studies.